{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:07:01Z","timestamp":1753891621740,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Hum. Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Some studies indicate a different response to treatment between migraine patients with and without aura.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine whether aura, or simple or complex aura subtypes, are clinical markers predicting response to preventive treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Conducted a retrospective cohort study at a headache clinic in a tertiary referral hospital. We included data from patients registered from 1 November 2014, to 30 June 2022, having migraine with or without aura, or with simple or complex aura, and who had received migraine preventive treatments with at least 3 months follow-up. The primary outcome was a response to preventive treatment defined as at least a 50% reduction from a baseline of monthly migraine or headache days (MMDs\/MHDs). Secondary outcomes were improvement in quality of life and disability scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For migraine patients with (45) and without (123) aura who took a migraine preventive with at least 3 months follow-up; except for median age, which was older for patients without aura, baseline sex, comorbidity, and migraine data were without significant difference including median history of migraine, chronic migraine subtype, chronic migraine with medication-overuse headache, median or mean MMDs\/MHDs, number of preventive medications used, or migraine preventive medication inhibiting spreading depolarizations. Treatment outcomes at 3 and 6 months follow-up were not significantly different between migraine patients with and without aura, or with simple and complex aura, but tended to be greater in those with aura and those with complex aura. After adjustment for baseline comorbidity, migraine subtypes, aura subtypes, the number of preventives used, history of migraine, and MMDs\/MHDs, we found no significant differences in 30% and 50% reduction from baseline of MMDs\/MHDs in 3 or 6 months or most recent follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Preventive treatment response tended to be associated with migraine aura subtypes. We found preventive treatment response tended to have more favorable outcomes in those with aura, especially those with complex aura.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnhum.2022.1065859","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T11:37:24Z","timestamp":1673264244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Preventive treatment response associated with migraine aura subtypes in a Thai population"],"prefix":"10.3389","volume":"16","author":[{"given":"Thanin","family":"Asawavichienjinda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin James","family":"Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","first-page":"126","article-title":"Acetylsalicylic acid in migraine with aura prevention \u2013 a retrospective study.","volume":"40","author":"Anoaica","year":"2014","journal-title":"Curr. Health Sci. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1515\/abm-2020-0021","article-title":"Thai-version migraine disability assessment (MIDAS) questionnaire: Concurrent validity, test\u2013retest reliability, internal consistency, and factors predictive for migraine-related disability.","volume":"14","author":"Asawavichienjinda","year":"2020","journal-title":"Asian Biomed."},{"key":"B3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1515\/abm-2018-0005","article-title":"Validity, reliability and sensitivity to change of the Thai version of the migraine-specific quality of life questionnaire version 2.1.","volume":"11","author":"Asawavichienjinda","year":"2017","journal-title":"Asian Biomed."},{"key":"B4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.20778","article-title":"Suppression of cortical spreading depression in migraine prophylaxis.","volume":"59","author":"Ayata","year":"2006","journal-title":"Ann. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.nbd.2010.10.014","article-title":"Migraine preventive drugs differentially affect cortical spreading depression in rat.","volume":"41","author":"Bogdanov","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/01.WNF.0000236766.08409.03","article-title":"Levetiracetam in the prophylaxis of migraine with aura: A 6-month open-label study.","volume":"29","author":"Brighina","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1007\/s10072-009-0074-2","article-title":"Efficacy of Ginkgolide B in the prophylaxis of migraine with aura.","volume":"30","author":"D\u2019Andrea","year":"2009","journal-title":"Neurol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1007\/s11739-010-0461-y","article-title":"Chronic headaches and medication overuse.","volume":"5","author":"Geppetti","year":"2010","journal-title":"Intern. Emerg. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1526-4610.2012.02288.x","article-title":"Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B.","volume":"53","author":"Grogan","year":"2013","journal-title":"Headache"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1046-4","article-title":"Differences in treatment response between migraine with aura and migraine without aura: Lessons from clinical practice and RCTs.","volume":"20","author":"Hansen","year":"2019","journal-title":"J. Headache Pain"},{"key":"B11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version).","volume":"33","year":"2013","journal-title":"Cephalalgia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition.","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-2982.2004.00805.x","article-title":"The international classification of headache disorders: 2nd edition.","volume":"24","year":"2004","journal-title":"Cephalalgia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ana.23653","article-title":"Acid-sensing ion channel 1: A novel therapeutic target for migraine with aura.","volume":"72","author":"Holland","year":"2012","journal-title":"Ann. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","article-title":"Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.","volume":"125","author":"Jakubowski","year":"2006","journal-title":"Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000117004","article-title":"Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat.","volume":"34","author":"Kaube","year":"1994","journal-title":"Eur. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0271678X18771440","article-title":"Systematic review of the pharmacological agents that have been tested against spreading depolarizations.","volume":"38","author":"Klass","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/jnnp.2005.063750","article-title":"Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura.","volume":"76","author":"Lampl","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.neurol.2021.07.010","article-title":"Migraine with aura.","volume":"177","author":"Lucas","year":"2021","journal-title":"Rev. Neurol. (Paris)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.33588\/rn.7211.2020577","article-title":"Degree of compliance with treatment at three months in migraine patients.","volume":"72","author":"Mar\u00edn-Gracia","year":"2021","journal-title":"Rev. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1177\/0333102418815487","article-title":"Proposal for a migraine aura complexity score.","volume":"39","author":"Petrusic","year":"","journal-title":"Cephalalgia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01112","article-title":"Application of the migraine aura complexity score (MACS): Clinical and neuroimaging study.","volume":"10","author":"Petrusic","year":"","journal-title":"Front. Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1468-2982.2009.01999.x","article-title":"Migraines with and without aura and their response to preventive therapy with topiramate.","volume":"30","author":"Reuter","year":"2010","journal-title":"Cephalalgia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European migraine & headache alliance (EMHA).","volume":"21","author":"Sacco","year":"2020","journal-title":"J. Headache Pain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000481252","article-title":"Aspirin prophylaxis for migraine with aura: An observational case series.","volume":"78","author":"Turk","year":"2017","journal-title":"Eur. Neurol."}],"container-title":["Frontiers in Human Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2022.1065859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T11:37:26Z","timestamp":1673264246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2022.1065859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":25,"alternative-id":["10.3389\/fnhum.2022.1065859"],"URL":"https:\/\/doi.org\/10.3389\/fnhum.2022.1065859","relation":{},"ISSN":["1662-5161"],"issn-type":[{"type":"electronic","value":"1662-5161"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1065859"}}